Access cutting-edge leiomyosarcoma treatment through this clinical trial at a research site in Los Angeles. Study-provided care at no cost to qualified participants.
Access leiomyosarcoma specialists in Los Angeles at no cost
This study follows strict safety protocols and ethical guidelines
All study-related leiomyosarcoma treatment provided free
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Independent Review Committee (IRC) when compared to doxorubicin administered as a single agent.
Sponsor: PharmaMar
Check if you qualify for this leiomyosarcoma clinical trial in Los Angeles, CA
If you're searching for leiomyosarcoma treatment options in Los Angeles, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Los Angeles research site is actively enrolling participants for this clinical trial. You'll receive care from experienced leiomyosarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.